VB 210

Drug Profile

VB 210

Alternative Names: VB-210; VITA-210

Latest Information Update: 03 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vitality Biopharma
  • Class Analgesics; Antispastics; Cannabinoids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Fibromyalgia; Irritable bowel syndrome; Muscle spasticity; Neuropathic pain

Most Recent Events

  • 03 Aug 2016 Vitality Biopharma has patents covering Cannabinoid prodrugs (Corporate presentation, July 2016)
  • 03 Aug 2016 Preclinical trials in Fibromyalgia in USA (PO) prior to August 2016
  • 03 Aug 2016 Preclinical trials in Irritable bowel syndrome in USA (PO) prior to August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top